SCHEMBL20312840

SCHEMBL20312840

CC(C)(C)Oc1ncnc2ccsc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.49
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
HTR2C P28335 1/20 0.39
ADORA2A P29274 2/20 0.38
ADORA2B P29275 1/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
PDE3B Q13370 2/20 0.38
PDE3A Q14432 2/20 0.38
PIP4K2C Q8TBX8 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
EGFR P00533 2/20 0.35
FADS1 O60427 1/20 0.35
PDPK1 O15530 1/20 0.35
PARP1 P09874 1/20 0.35
ADORA1 P30542 1/20 0.35
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7227815 0.80 AXL (0.53) AXLMKNK1MKNK2HTR2CADORA2A
SCHEMBL20319103 0.76 AXL (0.49) AXLMKNK1MKNK2HTR2CADORA2A
SCHEMBL4569215 0.73 AXL (0.53) AXLMKNK1MKNK2HTR2CADORA2A
SCHEMBL7880676 0.71 MAPT (0.55) AXLMKNK1MKNK2PDE4APDE4B
SCHEMBL424626 0.70 AXL (0.59) AXLMKNK1MKNK2HTR2CADORA2A
SCHEMBL23515581 0.69 AXL (0.49) AXLMKNK1MKNK2HTR2CADORA2A
SCHEMBL21567313 0.69 PDE4A (0.51) AXLMKNK1MKNK2HTR2CADORA2A
SCHEMBL7922052 0.68 ADORA2A (0.50) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL5637617 0.68 CTSK (0.41) AXLMKNK1MKNK2HTR2CADORA2A
SCHEMBL17211794 0.68 DRD1 (0.45) AXLMKNK1MKNK2ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-07-20 US disclosed
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-07-20 US disclosed
US-20180177784-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 US disclosed
US-20180177784-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180177784-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 AXL 3145/4885MKNK1 1316/4885MKNK2 1799/4885
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 AXL 3145/4885MKNK1 1316/4885MKNK2 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.